COYA/ 06/05/2026 · 7:29 AM Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech.
